SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

NCT05846789 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

168

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer
Triple Negative Breast Cancer
Estrogen-receptor-low Breast Cancer

Interventions

DRUG: SOC Chemotherapy
DRUG: Tocilizumab

Sponsor

Kathy Miller

Collaborators

[object Object]
[object Object]
[object Object]